Oncolytics Biotech Sets FDA Meeting for Registrational Colorectal Cancer Trial as Sites Activate Rapidly

summarizeSummary

Oncolytics Biotech announced rapid site activation in its randomized colorectal cancer trial and plans an August FDA meeting to discuss a registrational expansion, marking a key step toward potential approval.

check_boxKey Events · Product Development and Regulatory · ONCY

• FDA Meeting for Registrational Pathway

  A Type D meeting with the FDA is scheduled for the first half of August 2026 to discuss adding a registrational Part B to the REO 033 study, designed to support potential accelerated and full approval.

• Rapid Trial Site Activation

  By the end of July, approximately half of the planned clinical sites for Part A of REO 033 will be activated, with over 20 patients pre-identified across centers; the remaining sites are expected by the end of August.

• Initial Data Readout Expected Year-End 2026

  An initial tumor response update from Part A is expected by year-end 2026, and pending FDA feedback, enrollment in Part B could begin in Q1 2027.

• Going Concern Backdrop

  The progress comes amid a going-concern warning and ongoing ATM dilution; positive regulatory movement could improve financing options and partnership interest.

auto_awesomeAnalysis · ONCY · Life Sciences

Oncolytics Biotech is advancing its lead program toward a potential registration pathway. In August, the company will meet with the FDA to discuss adding a registrational Part B to the ongoing REO 033 study in RAS-mutant MSS metastatic colorectal cancer. This follows strong operational progress — half of the planned clinical sites are activating this month, and over 20 patients have been pre-identified. The update signals a shift from exploratory trials to a pivotal design that could support accelerated and full approval, a critical step for a biotech with a going-concern warning and limited cash runway. Positive FDA alignment would materially de-risk the program and open partnership opportunities.